SCHEMBL2108149

SCHEMBL2108149

CC(C)(O)CCCCCCc1cccc(C=Cc2cccc(O)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HMGCR P04035 1/20 0.57
AKR1B10 O60218 2/20 0.47
AKR1B1 P15121 2/20 0.47
LCK P06239 2/20 0.45
MMP1 P03956 2/20 0.42
MMP2 P08253 2/20 0.42
MMP9 P14780 2/20 0.42
ABL1 P00519 1/20 0.42
BCR P11274 1/20 0.42
MGLL Q99685 1/20 0.42
HDAC6 Q9UBN7 1/20 0.41
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2106283 1.00 HMGCR (0.57) HMGCRAKR1B10AKR1B1LCKMMP1
SCHEMBL2106285 1.00 HMGCR (0.57) HMGCRAKR1B10AKR1B1LCKMMP1
SCHEMBL2108148 1.00 HMGCR (0.57) HMGCRAKR1B10AKR1B1LCKMMP1
SCHEMBL6155060 0.93 HMGCR (0.56) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL6155055 0.93 HMGCR (0.56) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL2106841 0.93 HMGCR (0.56) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL2106842 0.93 HMGCR (0.56) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL2107875 0.92 HMGCR (0.57) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL2107876 0.92 HMGCR (0.57) HMGCRAKR1B10AKR1B1LCKABL1
SCHEMBL6154968 0.89 HMGCR (0.52) HMGCRAKR1B10AKR1B1LCKABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP claimed
EP-2879656-B2 DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE OREAL (FR) 2024-07-17 EP disclosed
US-11730682-B2 Self-standing cosmetic sheet L'OREAL (FR) 2023-08-22 US disclosed
EP-2879649-B2 DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT OREAL (FR) 2022-08-24 EP disclosed
EP-2836187-B1 SELF-STANDING COSMETIC SHEET OREAL (FR) 2021-12-08 EP disclosed
EP-2879656-B1 DYE COMPOSITION IN CREAM FORM COMPRISING AT LEAST ONE OIL AND LITTLE OR NO SOLID FATTY ALCOHOL, DYEING PROCESS AND SUITABLE DEVICE OREAL (FR) 2019-05-29 EP disclosed
US-10226411-B2 Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device L'OREAL (FR) 2019-03-12 US disclosed
US-10201483-B2 Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device L'OREAL (FR) 2019-02-12 US disclosed
EP-2879649-B1 DYEING COMPOSITION COMPRISING AT LEAST ONE FATTY SUBSTANCE, AT LEAST ONE OXIDIZING AGENT AND AT LEAST ONE NON-IONIC, ANIONIC AND AMPHOTERIC SURFACTANT OREAL (FR) 2018-11-07 EP disclosed
US-20180235849-A1 SELF-STANDING COSMETIC SHEET L'OREAL (FR) 2018-08-23 US disclosed
EP-1658838-A1 Emulsification system for use in cosmetics L'OREAL (FR) 2006-05-24 EP disclosed
US-20060039936-A1 Emulsification system for use in cosmetics L'OREAL (FR) 2006-02-23 US disclosed
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof L'OREAL (FR) 2005-08-04 US disclosed
EP-1559398-A1 Process for preparing a composition for the cosmetic treatment of keratinous materials on the basis of a pressurised fluid and vitamins L'OREAL (FR) 2005-08-03 EP disclosed
EP-1124779-B1 VITAMIN D ANALOGUES GALDERMA RES & DEV (FR) 2005-02-02 EP disclosed
US-6689922-B1 BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2004-02-10 US disclosed
US-20020197289-A1 Compositions and methods for combating the appearance of ageing L'OREAL (FR) 2002-12-26 US disclosed
EP-1262168-A1 Composition containing fibres to combat the skin aging process L'OREAL (FR) 2002-12-04 EP disclosed
EP-1124779-A1 VITAMIN D ANALOGUES Galderma Research & Development, S.N.C. (FR) 2001-08-22 EP disclosed
WO-2000026167-A1 VITAMIN D ANALOGUES GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2000-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10226411-B2 Dyeing composition comprising a fatty substance, a non-ionic guar gum, an amphoteric surfactant and a non-ionic or anionic surfactant, and an oxidizing agent, dyeing process and suitable device KRT18, OAT, DSG1 HMGCR 1759/4885AKR1B10 192/4885AKR1B1 277/4885
US-20020197289-A1 Compositions and methods for combating the appearance of ageing CYP24A1, CYP27B1, CYP2R1 HMGCR 283/4885AKR1B10 433/4885AKR1B1 197/4885
US-10201483-B2 Dye composition in cream form comprising at least one oil and little or no solid fatty alcohol, dyeing process and suitable device KRT18, CUTA, DSG1 HMGCR 844/4885AKR1B10 16/4885AKR1B1 59/4885
US-20180235849-A1 SELF-STANDING COSMETIC SHEET CUTA, DSG1, SUCLG1 HMGCR 565/4885AKR1B10 1893/4885AKR1B1 2813/4885
US-11730682-B2 Self-standing cosmetic sheet CUTA, DSG1, SUCLG1 HMGCR 565/4885AKR1B10 1893/4885AKR1B1 2813/4885
US-20050169945-A1 Composition for protecting keratin material, process of making, uses thereof KRT18, PROC, CUTA HMGCR 1113/4885AKR1B10 220/4885AKR1B1 501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.